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ABSTRACT
Introduction: Fosfomycin is a broad-spectrum
cell wall active agent that inhibits the MurA
enzyme involved in peptidoglycan synthesis
and is FDA-approved for treatment of uncom-
plicated urinary tract infections (UTIs) caused
by Escherichia coli and Enterococcus faecalis in
women. Data regarding the susceptibility of
recent UTI isolates to fosfomycin are limited.
Methods: This study compared the fosfomycin
susceptibility of 658 US UTI isolates with sus-
ceptibility to ciprofloxacin, levofloxacin, nitro-
furantoin, and trimethoprim/sulfamethoxazole
(SXT). Isolates included E. coli (n = 257), Kleb-
siella spp. (n = 156), Enterobacter spp. (n = 79),
Pseudomonas aeruginosa (n = 60), E. faecalis
(n = 54), and Proteus spp. (n = 52).
Extended-spectrum b-lactamase (ESBL)-produc-
ing E. coli, Klebsiella spp., and Proteus mirabilis,
ceftazidime-nonsusceptible P. aeruginosa and
Enterobacter spp., and vancomycin-nonsuscep-
tible E. faecalis were included.
Results: Overall, the minimum concentration
inhibiting 50% of isolates (MIC50) and 90% of
isolates (MIC90) for fosfomycin were 4 and
64 lg/mL, respectively. Of the 257 E. coli iso-
lates, 99.6% were susceptible to fosfomycin.
Ciprofloxacin, levofloxacin, SXT, and nitrofu-
rantoin susceptibility rates were 65.4%, 65.8%,
59.9%, and 90.3%, respectively. The fos-
fomycin-susceptibility rate for E. faecalis
(94.4%) was comparable with the nitrofuran-
toin-susceptibility rate (98.1%). Among the 144
ESBL-producing isolates, the fosfomycin MIC50
and MIC90 values were 2 and 32 lg/mL,
respectively. Fosfomycin MIC50 and MIC90 val-
ues were 16 and 128 lg/mL for the 38 cef-
tazidime-nonsusceptible Enterobacter isolates
and 64 and 128 lg/mL for the 15 cef-
tazidime-nonsusceptible P. aeruginosa isolates,
respectively.
Conclusion: These results demonstrate that
fosfomycin has in vitro activity against many
US UTI isolates, including drug-resistant iso-
lates, and may provide another therapeutic
option for treatment of UTIs caused by antibi-
otic-resistant pathogens.
Keywords: Antimicrobial; Fosfomycin; Urinary
tract infection
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Uncomplicated urinary tract infections (UTIs)
are one of the most common infections for
which antibiotics are prescribed, and there is a
current trend of increasing resistance to antibi-
otics typically used to treat these infections [1].
Contributing to this increased resistance is the
increased frequency of extended spectrum
b-lactamase (ESBL) production in organisms
causing UTIs, particularly Escherichia coli and
Klebsiella spp [2, 3].
Fosfomycin, trimethoprim/sulfamethoxa-
zole (SXT), and nitrofurantoin are the 3 treat-
ment options recommended for uncomplicated
UTIs by the Infectious Diseases Society of
America (IDSA) [1]. To safeguard against devel-
opment of resistance, fluoroquinolones, such as
ciprofloxacin and levofloxacin, are not recom-
mended for use in treatment of uncomplicated
UTI, despite their effectiveness. The IDSA
guidelines also recommend that ampicillin not
be used because of the increased prevalence of
ESBL-producing organisms in uncomplicated
UTIs, and that b-lactam antibiotics are used
only when other treatment options are
unavailable [1].
Ciprofloxacin and SXT resistance rates
among urine isolates from female outpatients
increased dramatically from 2003 to 2012,
especially among elderly outpatients, high-
lighting the need for other oral therapeutic
alternatives [4]. In a study of 1518 extraintesti-
nal E. coli isolates, including 1034 urinary iso-
lates, recovered from patients in the United
States and Germany between 2010 and 2011,
investigators observed resistance rates to nitro-
furantoin, ciprofloxacin, and SXT of 6.8%,
17.1%, and 26.9%, respectively [5].
Fosfomycin is a bactericidal, cell wall active
agent that binds to the MurA enzyme, thereby
inhibiting the first step in peptidoglycan for-
mation [6, 7]. It is approved, as fosfomycin
tromethamine for oral administration, by the
US Food and Drug Administration (FDA) for the
treatment of women with uncomplicated UTIs
(acute cystitis) caused by E. coli and Enterococcus
faecalis and has broad-spectrum activity in vitro
against Gram-positive and Gram-negative
bacteria [8]. Fosfomycin has recently received
renewed interest because of its activity against
multidrug-resistant bacteria [7, 9, 10] and the
low frequency of cross-resistance to it [8], likely
due to its unique mechanism of action. Fur-
thermore, fosfomycin has low and stable resis-
tance rates worldwide (1–3% of E. coli) despite
more than 20 years of clinical use in some
countries [11, 12]. In cases where fosfomycin
resistance does emerge, common mechanisms
include mutations affecting transport proteins
(e.g., GlpT and UhpT) and mutation of its tar-
get, MurA [11].
This study sought to compare the sensitivity
of UTI isolates to fosfomycin with sensitivity to
antibiotics commonly used for treatment of
UTIs, including ciprofloxacin, levofloxacin,
nitrofurantoin, and SXT, among US isolates
from the 2012 Assessing Worldwide Antimi-
crobial Resistance Evaluation (AWARE) surveil-
lance program. AWARE is a global surveillance
program established to monitor the suscepti-
bility of prespecified pathogens to a number of
antimicrobial agents [13]. Medical centers from
the nine US census regions contributed to the
database, with organisms collected being sent
for susceptibility testing to a central laboratory
(JMI Laboratories, North Liberty, IA, USA) [13].
Isolates for the present study were selected
proportionally to reflect the most commonly
isolated species from uncomplicated UTIs.
To test the hypothesis that fosfomycin has
activity against typical urinary tract patho-
gens, the activity against isolates with a resis-
tant phenotype, ESBL-positive E. coli,
Klebsiella spp., and Proteus spp. was assessed,
as was the activity of fosfomycin against cef-
tazidime-nonsusceptible P. aeruginosa, Enter-




Isolates collected during the 2012 AWARE
surveillance program were retrospectively
obtained from JMI Laboratories. Isolates were
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selected to obtain similar numbers of each
species from each of the nine US census
regions, based on their regional prevalence in
the AWARE program [14]. Isolates (n = 658)
included E. coli (n = 257), Klebsiella spp.
(n = 156), Enterobacter spp. (n = 79), P. aerugi-
nosa (n = 60), E. faecalis (n = 54), and Proteus
spp. (n = 52). Resistant isolates included
E. coli, Klebsiella spp., and P. mirabilis with an
ESBL phenotype; ceftazidime-nonsusceptible
P. aeruginosa and Enterobacter spp.; and van-
comycin-nonsusceptible E. faecalis. The
ESBL-phenotype was previously determined
by JMI Laboratories and defined according to
the Clinical and Laboratory Standards Insti-
tute (CLSI) ESBL screening criteria (cef-
tazidime and/or ceftriaxone and/or aztreonam
minimum inhibitory concentration [MIC]
value [1 lg/mL) [15]. Ceftazidime non-sus-
ceptibility (MICs C8 lg/mL) was used to cate-
gorize Enterobacter spp. Ceftriaxone and
vancomycin susceptibilities were determined
by JMI Laboratories using CLSI breakpoints
[15]. Genotype determinations were made by
JMI Laboratories using Check-points microar-
ray kit CT–101 (Check-Points, Wageningen,
The Netherlands) [16, 17]. This kit has the
capability to detect blaCTX-M Groups 1, 2,
8 ? 25, and 9, blaTEM wild-type (wt) and ESBL,
blaSHV wt and ESBL, blaACC, blaACT/MIR, blaC-
MYII, blaDHA, blaFOX, blaKPC, and blaNDM-1 (but
not blaOXA-48, blaIMP or blaVIM).
Antibiotics included in this study were fos-
fomycin (P5396-5G, lot BCBJ9873V; Sigma-Al-
drich, St. Louis, MO, USA), ciprofloxacin
(1134335, lot J0H307; USP, Rockville, MD,
USA), levofloxacin (28266-1G-F, lot 1425507;
Sigma-Aldrich, St. Louis, MO, USA), nitrofu-
rantoin (1464001, lot K01060; USP), trimetho-
prim (Sigma T7883-5G, lot BCBB6418;
Sigma-Aldrich), and sulfamethoxazole (Sigma
S7507-10G, lot 048K0124; Sigma-Aldrich).
Reagents used in this study included
Mueller–Hinton agar (MHA; BBL 211438, lot
3217394; BD Diagnostic Systems, Sparks, MD,
USA), glucose-6-phosphate (G7879-1G, lot
031M7004V; Sigma-Aldrich), and cation-ad-
justed Mueller–Hinton broth (CAMHB; BBL
21322; BD Diagnostic Systems).
Agar Dilution
Minimum inhibitory concentration for fos-
fomycin was determined by agar dilution
according to CLSI documents M07-A9 and
M100-S24 [15, 18]. MHA was prepared accord-
ing to manufacturer’s instructions followed by
the addition of glucose-6-phosphate to a final
concentration of 25 lg/mL. Fosfomycin was
added to MHA in 2-fold serial dilutions at con-
centrations ranging from 0.25 to 256 lg/mL.
Approximately 104 colony-forming units (CFU)/
spot were added to plates. After incubation at
35 ± 2 C for 16–20 h, the MIC was recorded as
the lowest concentration of antimicrobial agent
that completely inhibited visible growth.
Broth Microdilution
Minimum inhibitory concentration values for
ciprofloxacin, levofloxacin, nitrofurantoin, and
SXT were determined by broth microdilution
methods according to CLSI documents M07-A9
and M100-S24 [15, 18], with testing of appro-
priate quality control strains.
Antibiotic test plates were prepared in-house
using a twofold dilution series in 96-well
round-bottom plates containing antibiotic (109
solution). Bacterial suspensions were diluted in
CAMHB and added to the antibiotic test plates
to yield a final culture density of 5 9 105 CFU/
mL. After incubation for 18 h at 35 ± 2 C, the
MIC was recorded as the lowest concentration
where there was no visible bacterial growth.
Analysis
Minimum inhibitory concentration values were
interpreted with respect to CLSI interpretative
criteria for E. coli and E. faecalis [fosfomycin
breakpoints were MIC B64 lg/mL (susceptible),
MIC = 128 lg/mL (intermediate), and MIC
C256 lg/mL (resistant)] [15].
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
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committee on human experimentation (insti-
tutional and national) and with the Helsinki
Declaration of 1964, as revised in 2008.
Informed consent was not required because
isolates used in this study were from a previ-
ously conducted surveillance program and no
patient-identifiable data were held by the
investigators undertaking the current research.
RESULTS
A total of 658 UTI isolates were tested from the
nine US census regions representing defined
numbers of isolates of selected species col-
lected during the 2012 AWARE surveillance
program. Overall, MIC values for fosfomycin
ranged from B0.25 to [256 lg/mL, and the
fosfomycin MIC50 and MIC90 values for all
isolates were 4 and 64 lg/mL, respectively
(Table 1). A total of 202 isolates had a resistant
phenotype (Table 2). Overall, 21.9% (144/658)
of isolates were of the ESBL-phenotype (E. coli,
K. pneumoniae, K. oxytoca, and P. mirabilis
only), 53 (8.1%) were ceftazidime-nonsuscep-
tible E. cloacae and P. aeruginosa isolates and 5
(0.8%) were vancomycin-nonsusceptible
E. faecalis isolates.
Susceptibility results of the 257 E. coli isolates
tested are shown in Table 1. The fosfomycin
MIC50 and MIC90 values for E. coli were 1 and
4 lg/mL, respectively. Only one (0.4%) E. coli
isolate (an ESBL-phenotype) was resistant to
fosfomycin. Susceptibility results of the 76
E. coli isolates with an ESBL phenotype are
shown in Table 2.
Summaries of pathogen susceptibilities are
provided in Tables 1 and 2. Fosfomycin had
MIC50 and MIC90 values of 8 and 32 lg/mL for
Klebsiella spp., 4 and 32 lg/mL for Proteus spp.,
and 16 and 32 lg/mL for Enterobacter spp.,
respectively (Table 1). Most E. faecalis isolates
(94.4%) were susceptible to fosfomycin
(Table 1). Fosfomycin MIC50 and MIC90 values
against P. aeruginosa were 64 and 128 lg/mL,
respectively (Table 1). Among all 202 resistant
organisms tested (including those with an ESBL
phenotype, ceftazidime-nonsusceptible
Gram-negative pathogens, and van-
comycin-nonsusceptible E. faecalis), fosfomycin
had MIC50 and MIC90 values of 4 and 64 lg/mL,
respectively (Table 2). Twenty-four of these iso-
lates (23 K. pneumoniae and 1 E. coli) were car-
bapenemase producers based on the detection
of a KPC gene and on being nonsusceptible to
meropenem (data not shown). All but two of
these carbapenem resistant isolates had MICs
indicative of susceptibility to fosfomycin (based
on the CLSI interpretive guidelines for E. coli
and E. faecalis, one was intermediate and one
resistant). There were only 5 vancomycin-non-
susceptible E. faecalis tested, but all were sus-
ceptible to fosfomycin with MIC values B64 lg/
mL (Table 2). Fosfomycin MIC50 and MIC90
values for Klebsiella spp. with an EBSL-pheno-
type were 8 and 128 lg/mL and for cef-
tazidime-nonsusceptible Enterobacter spp. were
16 and 128 lg/mL, respectively (Table 2). By
comparison, the fosfomycin MIC50 for cef-
tazidime-nonsusceptible P. aeruginosa was
numerically higher (64 lg/mL), whereas the
MIC90 value was similar (128 lg/mL; Table 2).
In total, 17 (2.6%) isolates had MIC values
suggesting resistance to fosfomycin (data not
shown), including E. coli (ESBL-phenotype;
n = 1), ceftazidime-nonsusceptible E. cloacae
(n = 3), vancomycin-susceptible E. faecalis
(n = 1), K. pneumoniae [n = 10; ESBL-phenotype
(n = 5) and non-ESBL-phenotype (n = 5)],
non-ESBL-phenotype P. mirabilis (n = 1), and
ceftazidime-nonsusceptible P. aeruginosa
(n = 1). Among those isolates with an
ESBL-phenotype that were fosfomycin-‘‘resis-
tant’’ (n = 6), there was no common b-lactamase
gene detected among all the isolates, and there
was no clear correlation between b-lactamase
genes present and fosfomycin resistance (data
not shown). Three isolates with blaCTX-M genes
were resistant to fosfomycin (2 K. pneumoniae
and 1 E. coli).
DISCUSSION
Overall, fosfomycin exhibited antibacterial
activity against the panel of 658 organisms.
With the exception of 1 isolate, all E. coli iso-
lates tested were susceptible to fosfomycin. By
comparison, the E. coli susceptibility rates were
markedly lower for the other antibiotics tested,
Infect Dis Ther
Table 1 Pathogen characteristics and antibiotic susceptibilities
MIC50 MIC90 Range S (%) I (%) R (%)
All organisms (n = 658)
Fosfomycin 4 64 B0.25 to[256 – – –
Ciproﬂoxacin 0.06 [32 0.004 to[32 68.4 3.0 28.6
Levoﬂoxacin 0.25 32 0.016 to[32 70.4 1.7 28.0
Nitrofurantoina 32 128 1 to[128 56.4 23.3 20.3
SXTb 0.5 [32 0.06 to[32 63.4 – 36.6
E. coli (n = 257)
Fosfomycin 1 4 B0.25 to[256 99.6 0.0 0.4
Ciproﬂoxacin 0.03 [32 0.004 to[32 65.4 0.0 34.6
Levoﬂoxacin 0.06 32 0.016 to[32 65.8 0.4 33.9
Nitrofurantoin 16 32 2 to[128 90.3 5.8 3.9
SXT 0.5 [32 0.06 to[32 59.9 – 40.1
Klebsiella spp. (n = 156)c
Fosfomycin 8 32 0.5 to[256 – – –
Ciproﬂoxacin 0.06 [32 0.008 to[32 66.0 1.9 32.1
Levoﬂoxacin 0.125 [32 0.016 to[32 68.6 1.3 30.1
Nitrofurantoin 64 128 2 to 128 9.0 41.0 50.0
SXT 0.5 [32 0.06 to[32 58.3 – 41.7
Proteus spp. (n = 52)d
Fosfomycin 4 32 B0.25 to[256 – – –
Ciproﬂoxacin 0.03 4 0.016 to[32 86.5 1.9 11.5
Levoﬂoxacin 0.06 4 B0.03 to 32 88.5 3.8 7.7
Nitrofurantoin – – – – – –
SXT 0.25 [32 0.06 to[32 73.1 – 26.9
Enterobacter spp. (n = 79)e
Fosfomycin 16 32 0.5 to[256 – – –
Ciproﬂoxacin 0.03 32 0.008 to[32 83.5 5.1 11.4
Levoﬂoxacin 0.06 32 0.016 to[32 83.5 5.1 11.4
Nitrofurantoin 64 128 1 to 128 11.4 59.5 29.1
SXT 0.5 [32 0.06 to[32 78.5 – 21.5
CAZ S Enterobacter spp. (n = 41)f
Fosfomycin 16 32 0.5 to 128 – – –
Ciproﬂoxacin 0.03 0.25 0.016 to 32 97.6 0.0 2.4
Levoﬂoxacin 0.06 0.25 0.016 to 32 97.6 0.0 2.4
Nitrofurantoin 64 128 2 to 128 7.3 58.5 34.1
SXT 0.25 2 B0.25 to[32 90.2 – 9.8
E. faecalis (n = 54)
Fosfomycin 32 64 16 to[256 94.4 3.7 1.9
Ciproﬂoxacin 1 [32 0.5 to[32 51.9 16.7 31.5
Levoﬂoxacin 1 [32 0.5 to[32 68.5 0.0 31.5
Nitrofurantoin 8 16 8 to 64 98.1 1.9 0.0
SXT – – – – – –
VAN S E. faecalis (n = 49)
Fosfomycin 64 64 16 to 256 93.9 4.1 2.0
Ciproﬂoxacin 1 [32 0.5 to[32 57.1 18.4 24.5
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a significant finding given that E. coli is the
pathogen most commonly found in UTI infec-
tions. The fosfomycin susceptibility rate for
E. coli isolates with an ESBL-phenotype was
markedly higher than any other antibiotic tes-
ted. Among the isolates with an ESBL pheno-
type, blaCTX-M group 1 and non-ESBL blaTEM
were the most common b-lactamase genes
detected (data not shown).
A study of E. coli isolated from urine of US
outpatients from 2000 to 2010 reported resis-
tance rates for ciprofloxacin, nitrofurantoin,
and SXT that were slightly lower than those
observed in the present study; this likely reflects
a continued increase in resistance over the
period 2010 to 2012 similar to that observed for
the period 2000 to 2010 [20]. A recent study of
E. coli isolates from patients with UTI in Canada
during the period from 2010 to 2013 demon-
strated susceptibility rates similar to the present
study for fosfomycin (99.4% vs. 99.6%, respec-
tively) and nitrofurantoin (96.1% vs. 90.3%,
respectively) and higher than observed for
ciprofloxacin (77.4% vs. 65.4%, respectively),
and SXT (74.7% vs. 59.9%, respectively) [21]. US
researchers also found E. coli to commonly
exhibit susceptibility to fosfomycin (100%, tes-
ted using agar dilution) and nitrofurantoin
(98.0%) [19].
Compared with the present study, similar
susceptibility rates were also reported among
ESBL-producing E. coli isolates from patients
with UTI in the Canadian study for fosfomycin
(100%) and nitrofurantoin (83.3%), with SXT
(35.7%), and ciprofloxacin (9.5%) rates being
somewhat lower [21]. Similarly, in a small US
study, ESBL-producing E. coli isolates were sus-
ceptible to fosfomycin (96.7%; MIC values ran-
ged from 0.25 to 4 lg/mL), but less so to
nitrofurantoin (76.7%; MIC values of 8–64 lg/
mL; susceptibility breakpoint B32 lg/mL) [22].
Another study of E. coli isolated from patients
with UTI in China from 2004 to 2012 showed
that fosfomycin susceptibility rates were high
Table 1 continued
MIC50 MIC90 Range S (%) I (%) R (%)
Levoﬂoxacin 1 [32 0.5 to[32 75.5 0.0 24.5
Nitrofurantoin 8 16 8 to 64 98.0 2.0 0.0
SXT – – – – – –
P. aeruginosa (n = 60)
Fosfomycin 64 128 2 to[256 – – –
Ciproﬂoxacin 0.25 32 0.008 to[32 66.7 5.0 28.3
Levoﬂoxacin 1 [32 0.016 to[32 63.3 3.3 33.3
Nitrofurantoin – – – – – –
SXT – – – – – –
CAZ S P. aeruginosa (n = 45)
Fosfomycin 64 128 4 to 128 – – –
Ciproﬂoxacin 0.125 32 0.008 to[32 84.4 0.0 15.6
Levoﬂoxacin 0.5 [32 0.016 to[32 80.0 4.4 15.6
Nitrofurantoin – – – – – –
SXT – – – – – –
Percent susceptible not calculable due to organisms in the group without CLSI breakpoints indicated by ‘‘–’’
CAZ S ceftazidime-susceptible, I intermediate, MIC50 minimum concentration that inhibits 50% of isolates, MIC90 minimum concentration that inhibits
90% of isolates, R resistant, S susceptible, SXT trimethoprim/sulfamethoxazole, VAN S vancomycin-susceptible
a P. aeruginosa and Proteus spp. (n = 546) are intrinsically resistant to nitrofurantoin and were not included in the calculations
b P. aeruginosa and E. faecalis (n = 544) are intrinsically resistant to SXT, so those organisms were not included in the calculations
c K. pneumoniae (n = 36); K. oxytoca (n = 20)
d P. mirabilis (n = 34); P. vulgaris (n = 18)
e E. cloacae (n = 49); E. aerogenes (n = 30)
f E. cloacae (n = 26); E. aerogenes (n = 15)
Infect Dis Ther
Table 2 Pathogen characteristics and antibiotic susceptibilities for resistant isolates
MIC50 MIC90 Range S (%) I (%) R (%)
Resistant organisms (n = 202)
Fosfomycin 4 64 B0.25 to[256 – – –
Ciproﬂoxacin 32 [32 0.016 to[32 32.2 5.0 62.9
Levoﬂoxacin 16 [32 0.016 to[32 33.7 3.0 63.4
Nitrofurantoina 64 128 1 to 128 41.8 25.5 32.6
SXTb [32 [32 0.06 to[32 40.7 – 59.3
ESBL-phenotype (n = 144)c
Fosfomycin 2 32 B0.25 to[256 – – –
Ciproﬂoxacin [32 [32 0.016 to[32 25.7 2.1 72.2
Levoﬂoxacin 16 [32 0.016 to[32 27.8 1.4 70.8
Nitrofurantoind 64 128 8 to 128 46.8 17.0 36.2
SXT [32 [32 0.06 to[32 34.0 – 66.0
E. coli ESBL-phenotype (n = 76)
Fosfomycin 1 4 B0.25 to[256 98.7 0.0 1.3
Ciproﬂoxacin [32 [32 0.016 to[32 28.9 0.0 71.1
Levoﬂoxacin 16 32 0.03 to[32 28.9 1.3 69.7
Nitrofurantoin 16 64 8 to 128 82.9 9.2 7.9
SXT [32 [32 0.06 to[32 43.4 – 56.6
Klebsiella spp.: ESBL-phenotype (n = 65)e
Fosfomycin 8 128 1 to[256 – – –
Ciproﬂoxacin 32 [32 0.016 to[32 21.5 4.6 73.8
Levoﬂoxacin 16 [32 0.016 to[32 26.2 1.5 72.3
Nitrofurantoin 128 128 16 to[256 4.6 26.2 69.2
SXT [32 [32 0.06 to[32 23.1 – 76.9
P. mirabilis: ESBL-phenotype (n = 3)
Fosfomycin NC NC 0.5 to 2 – – –
Ciproﬂoxacin NC NC 0.03 to[32 33.3 0.0 66.7
Levoﬂoxacin NC NC 0.125 to 32 33.3 0.0 66.7
Nitrofurantoin – – – 0.0 33.3 66.7
SXT NC NC 1 to[32 33.3 – 66.7
CAZ NS Enterobacter spp. (n = 38)f
Fosfomycin 16 128 0.5 to[256 – – –
Ciproﬂoxacin 0.25 [32 0.008 to[32 68.4 10.5 21.1
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(93.4–99.4%), despite high ESBL-producing
phenotype rates of 58.1% among isolates tested;
ESBL-producing E. coli susceptibility rates for
fosfomycin (93.8%) and nitrofurantoin (86.2%)
were also similar to those reported here for
isolates with ESBL phenotypes [23]. Over the
period 2010 through to 2013, susceptibility
rates of E. coli isolates were similarly high for
fosfomycin (95.8%) in multidrug-resistant uri-
nary isolates from a Veterans Affairs population
in Boston, MA, USA [24].
The reduced susceptibility of cUTI isolates
Klebsiella and Enterobacter spp. to nitrofurantoin
observed in this study was also observed in a
study conducted in Canada in 2001 (suscepti-
bility rates of 69.2% and 63.0%, respectively)
[25], and in a recent US study (susceptibility
rates of 52.3% and 71.9%, respectively) [19].
Similarly, in the Boston area Veterans Affairs
population, 64.0% of Klebsiella spp. were sus-
ceptible to nitrofurantoin, but in contrast to the
current study slightly more than half of the
multidrug-resistant isolates were susceptible to
fosfomycin [24]. Ongoing surveillance is needed
to assess the activity of nitrofurantoin against
contemporary isolates of these organisms.
Table 2 continued
MIC50 MIC90 Range S (%) I (%) R (%)
Levoﬂoxacin 0.25 32 0.03 to[32 68.4 10.5 21.1
Nitrofurantoin 64 128 1 to 128 15.8 60.5 23.7
SXT 0.5/9.5 [32/608 0.06 to[32 65.8 – 34.2
CAZ NS P. aeruginosa (n = 15)
Fosfomycin 64 128 2 to[256 – – –
Ciproﬂoxacin 16 32 0.125 to 32 13.3 20.0 66.7
Levoﬂoxacin 16 [32 0.5 to[32 13.3 0.0 86.7
Nitrofurantoin – – – – – –
SXT – – – – – –
VAN NS E. faecalis (n = 5)
Fosfomycin NC NC 32 to 64 100.0 0.0 0.0
Ciproﬂoxacin NC NC [32 to[32 0.0 0.0 100.0
Levoﬂoxacin NC NC 32 to[32 0.0 0.0 100.0
Nitrofurantoin NC NC 8 to 16 100.0 0.0 0.0
SXT – – – – – –
Percent susceptible not calculable due to organisms in the group without CLSI breakpoints indicated by ‘‘–’’
CAZ NS ceftazidime-nonsusceptible, ESBL extended spectrum b-lactamase, I intermediate, MIC50 minimum concentration
that inhibits 50% of isolates, MIC90 minimum concentration that inhibits 90% of isolates, R resistant, S susceptible, SXT
trimethoprim/sulfamethoxazole, VAN NS vancomycin-nonsusceptible
a P. aeruginosa and Proteus spp. (n = 184) are intrinsically resistant to nitrofurantoin and were not included in the
calculations
b P. aeruginosa and E. faecalis (n = 182) are intrinsically resistant to SXT and were not included in the calculations
c E. coli (n = 76), K. pneumoniae (n = 59), K. oxytoca (n = 6), and P. mirabilis (n = 3)
d P. mirabilis (n = 141) are intrinsically resistant to nitrofurantoin and were not included in the calculations
e K. pneumoniae (n = 59) and K. oxytoca (n = 6)
f E. cloacae (n = 23) and E. aerogenes (n = 15)
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Overall, the rate of fosfomycin resistance was
low in this study, as has been recently reported
in general populations in the US (resistance
rates of 1.5% and 3.3%) [19, 22], but not in a
predominantly male population from the Bos-
ton area (overall resistance rate of 21.6%) [24].
There are several mechanisms by which bacteria
become resistant to fosfomycin, including
amino acid substitutions that modify the fos-
fomycin target MurA, mutations that affect
fosfomycin transporters, and acquisition of
genes that encode enzymes that inactivate fos-
fomycin [11]. Although fosfomycin resistance is
not typically associated with b-lactamase pro-
duction, one study demonstrated that the fosA3
gene, which encodes a fosfomycin-inactivating
enzyme, can be associated with blaCTX-M genes
in E. coli [26]. This may explain the fosfomycin
resistance observed in a few of the isolates
assessed in this study. Further testing is needed
to determine whether these fosfomycin- resis-
tant pathogens encode the fosA3 gene.
This study shares the limitations inherent to
in vitro trials, including the potential limited
applicability to the clinical setting. In this case,
our study is further limited by relying on a subset
of data from the AWARE surveillance program.
The data presented here represent a subset of
surveillance results of US isolates from the 2012
AWARE surveillance program, and although the
data have been stratified by region and by patho-
gen to reflect the original database, it is possible
that the susceptibility patterns of the actual iso-
lates included inour studymayhavediffered from
the underlying AWARE data. Furthermore, the
isolates that we could assess were limited to those
isolates collected through the AWARE surveil-
lance program and duplicate MIC testing was not
performed. Nonetheless, the AWARE surveillance
program offers a useful dataset from which to
assess susceptibility patterns at a point in time.
The clinical applicability of our study may be
further limited as susceptibility rates may change
over time or differ in other regions of the world.
CONCLUSION
The data reported in this study demonstrate
that, compared with the other antibiotics
tested, fosfomycin has greater in vitro activity
against US UTI isolates, including Enterobacte-
riaceae with ESBL-phenotypes and other
drug-resistant isolates. The susceptibility data
for US surveillance isolates in this study should
serve as a baseline for benchmarking any future
changes in the susceptibility of uropathogens to
fosfomycin as it becomes more widely used for
the treatment of infections caused by resistant
pathogens.
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